Prostaglandin E1 for treatment of erectile dysfunction (Q24247137)

Europe PubMed Central

title

Prostaglandin E1 for treatment of erectile dysfunction (English)

0 references

1 reference

1 reference

Riccardo Urciuoli

1

0 references

Teresa Anna Cantisani

2

0 references

Marzia Carlini

3

0 references

Marta Giuglietti

4

0 references

Fabio Massimo Botti

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 April 2004

0 references

published in

0 references

cites work

Intracavernosal versus intraurethral alprostadil: a prospective randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

A prostaglandin E1 dose-response study in man.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Prostaglandin E1 therapy for impotence, comparison with papaverine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Prospective comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021

MUSE: clinical experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001784.PUB2

7 January 2021